In 1952 cortisone therapy was initiated in two patients with far advanced prostatic carcinoma.2 As part of the study of those patients, determinations were made of urinary 17-ketosteroid excretion before and during therapy with cortisone. Rather large increases in excretion of 17-ketosteroids were noted during the administration of high doses of cortisone in both patients. This unexpected finding led to an investigation of the effect of cortisone on 17-ketosteroid excretion, the preliminary results of which are now being reported.
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The following somewhat arbitrary procedure was adopted for the initial phase of this study. Three 24-hour urine samples were collected for baseline 17-ketosteroid determination. Cortisone acetate was then administered orally for three days in four doses of 75 mg. each, a total of 300 mg. per day; three 24-hour urine specimens were collected during this "cortisone period." Whenever possible, the experiment was completed during six consecutive days, during which no major change in the patient's course or treatment took place. In a few instances this was not possible, and the baseline and cortisone periods were not similar in all respects. Occasionally, three specimens could not be collected for each period, and base-line or cortisone figures are based on one or two determinations. With one exception, all patients were hospitalized during the study.
The 17-ketosteroid determinations were performed in triplicate by a modification of the method of Masuda and Thuline,' using the Zimmerman reaction. Determinations on all six urine specimens were usually performed on the same day, under identical conditions, by a technician who did not know the patient's diagnosis.
Studies have been completed on eighteen patients. Six of them had carcinoma of the prostate. Different stages of this disease were represented; for example, in one case the disease was sufficiently localized to warrant treatment by radical prostatectomy; two presented extensive bone metastases, pulmonary involvement, and anemia. Eight patients were "controls" without neoplastic disease. Three of these were essentially well individuals undergoing rehabilitation from paralytic poliomyelitis. The others were chronically ill patients. Four patients had inoperable malignant disease not known to be primary in the prostate. One of the "control" patients was a young woman; all other patients were men. Table 1 summarizes the major features of these eighteen case histories.
RESULTS
The 17-ketosteroid determinations on this group of eighteen patients are presented in Table 2 . The base-line values fell within the usual range and varied as would be expected with sex and age, except that several of the patients with carcinoma of the prostate excreted somewhat larger amounts than usual for elderly men. In general, there was relatively little variation among the three base-line urine specimens from any one patient.
There was considerable variation in 17-ketosteroid excretion during the first day cortisone was administered. In some cases it was close to the baseline figure; in others it was in the same range as the excretion during the second and third day. Because of the variability, this figure was not used in making comparisons between different groups of patients.
During the second and third cortisone days the patients without malignant neoplasms excreted somewhat larger amounts of 17-ketosteroids than during the base-line period. The average increment over the base line for this group of eight patients was 4.3 mg. per 24 hours. Individual values ranged from a decrement of 2.3 mg. to an increment of 11.7 mg. In one patient the excretion on the third day exceeded that on the second day by 5 mg. or more; in another, the reverse was true. The averages for the second and third days were not significantly different.
Considerable increase in 17-ketosteroid excretion during the second and third days of cortisone administration was noted in all six patients with carcinoma of the prostate. The average increment over the base-line for this group was 21.8 mg. per 24 hours. This was five times the figure for the "control" group. Individual increments ranged from 9.1 mg. to 34.7 mg. The smallest average increment for any patient was 17.1 mg. In three patients the excretion on the third day exceeded that on the second by 10 mg. or more. In no patient did the second day's excretion significantly exceed the third. The average for the third day was appreciably higher than the second. These figures suggest that, in contrast to the patients with non- in Figure 1 , there is no overlap between the two groups on either the second or the third cortisone day, and the mean increment in 17-ketosteroid excretion in the latter group is more than five times that of the former. It is possible that the difference would have been even greater had the experimental period been longer. The data suggest that 17-ketosteroid excretion was still rising on the third cortisone day in some patients with prostatic carcinoma; this did not seem to be true of the non-malignant group.
There are relatively few data in the literature on 17-ketosteroid excretion by patients receiving doses of cortisone comparable to those used in this study. Burstein creted by an essentially healthy man who ingested 2,500 mg. of cortisone over a five-day period. Calculations from their data indicate that there was no rise in 17-ketosteroids during this period. Sandberg, et al." noted a small increment in the 17-ketosteroid excretion of a 42-year-old man with rheumatoid arthritis during a course of therapy with 300 mg. of cortisone daily. Maddock, Chase, and Nelson' determined 17-ketosteroid excretion of four male patients with rheumatoid arthritis who were receiving 500-800 mg. of cortisone daily by intramuscular injection. They reported increases of 3 to 13 mg. per 24 hours over base-line excretion. The findings in these three studies are consistent with our "non-malignant" response.
Valk and Owens7 and Harrison, Thorn, and Jenkins' indicated that administration of large doses of cortisone to patients with carcinoma of the prostate resulted in increased 17-ketosteroid excretion. Figures pertinent to our study are given for only one patient-Case 3 of the latter report. This patient's 17-ketosteroid excretion rose from 6 to 47 mg. per 24 hours after five days of administration of hydrocortisone at a dose of 300 mg. per day. This is consistent with our "positive" response.
Discussion of the mechanisms involved in the production of these differences in ketosteroid excretion must await the accumulation of additional data. Several conclusions may be drawn from this preliminary study. These differences do not reflect the over-all clinical status or nutritional balance of the patients. Two of the patients with prostatic carcinoma were in excellent condition except for their local disease. The sickest patient in this series, on the other hand, was Case 5, a "control." Non-malignant disease of the prostate did not produce a "positive" response. There was no correlation with acid phosphatase, alkaline phosphatase, or the presence or absence of demonstrable bone involvement.
The sensitivity of this response is not known. None of the patients in this series could be said to have "early" or "questionable" cancer, although two had disease of relatively limited extent. Of considerable interest is the question whether the phenomenon under study is especially related to prostatic malignancy, or whether it is common to many forms of cancer. Studies now under way should shed light on this and other questions, which largely determine the usefulness of a "cancer test."
The cortisone "test" was ordinarily performed only upon patients whose diagnoses were known. An interesting exception was Case 16. This 74-year-old man was admitted in a semicomatose state, with fever, stiff neck, and a type III pneumococcal bacteremia. He improved gradually on intensive antibiotic therapy. X-ray examinations revealed increased densities in the ribs, spine, pelvis, and femora. Clinical opinion was divided, with some observers favoring the diagnosis of metastatic carcinoma of bone, and others, Paget's disease. Repeated careful examinations revealed no primary site of carcinoma. Two bone marrow aspirations and a needle biopsy of the prostate were negative. However, the 17-ketosteroid excretion rose sharply during cortisone administration. Largely on the strength of this finding, surgical biopsy of a rib was performed, and metastatic carcinoma was demonstrated. The primary site has not yet been discovered.
SUMMARY
The effect of large doses of cortisone on 17-ketosteroid excretion was studied in patients with and without malignant neoplastic disease. Eight patients without cancer showed little or no increase in urinary 17-ketosteroids while receiving 300 mg. of cortisone acetate per day. Six patients with carcinoma of the prostate showed a marked increase in 17-ketosteroid excretion under similar conditions of cortisone administration. There was no overlap between these two groups. Three of four patients with other malignancies showed a response similar to that of the patients with prostatic cancer. The possibility that this phenomenon may have some clinical usefulness as a "cancer test" is being investigated.
